Trending Now
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) Announces Findings Supporting Use of CM-101...
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) has reported two scientific presentations, including patient and preclinical findings supporting the possible use of its lead treatment candidate,...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
NovaBay Pharmaceuticals Inc. (NYSEAMERICAN: NBY) Signs Agreement To Acquire $15 Million...
NovaBay Pharmaceuticals Inc. (NYSEAMERICAN: NBY) has announced the signing of a definitive agreement to buy DERMAdoctor LLC for $15 million comprising of $12 million...
MAKE IT MODERN
LATEST REVIEWS
Seelos Therapeutics Inc. (NASDAQ:SEEL) Announce Commencement Of SLS-004 Preclinical Study In...
Seelos Therapeutics Inc. (NASDAQ:SEEL) has announced the commencement of a preclinical SLS-004 study in Parkinson’s disease through a lentiviral vector that is all in...
MAKE IT MODERN
PERFORMANCE TRAINING
Sarepta Therapeutics Inc. (NASDAQ:SRPT) Posts Net Product Revenue Of $121.4 Million In Q3 2020
Sarepta Therapeutics Inc. (NASDAQ:SRPT) has announced its Q3 2020 financial results with net product sales up 23% YoY to $121.4 million.
Sarepta reports 23% YoY...
Recession-free stocks to place on top of radar (DG,TGT,DLTR,GOOG,BIG)
Only time will tell if we are heading into a recession as the central bank’s aggressive rate hikes start to slow the...
Amarin Corporation Plc (NASDAQ:AMRN) Reports A Growth Of 34% YoY In Q2 2020 Revenues:...
Amarin Corporation Plc (NASDAQ:AMRN) posted revenues of $135.3 million in Q2 2020. President of Amarin, John F. Thero said Q2 2020 is a challenging...
Brainsway (NASDAQ:BWAY) chart suggest bullish action and long term potential
Brainsway (NASDAQ:BWAY) had recent big insider buys around $2 suggesting a positive speculation of something big may be brewing at the company....
Protagonist Therapeutics (NASDAQ: PTGX) Receives $25 Million Milestone Payment from Partnership with Janssen
Protagonist Therapeutics (NASDAQ: PTGX) has announced a $25 million milestone payment from its partnership with Janssen Biotech Inc. after dossing the third subject in...
MAKE IT MODERN
